Basilea Pharmaceutica BSLN

SWX: BSLN | ISIN: CH0011432447   31/05/2024
43,70 CHF (+0,23%)
(+0,23%)   31/05/2024

16 mei 2024 · Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea · Persbericht

3 mei 2024 · Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024 · Persbericht

24 april 2024 · Basilea shareholders approve all proposals of the board of directors at the annual general meeting · Persbericht

9 april 2024 · Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics · Persbericht

4 april 2024 · Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications · Persbericht

11 maart 2024 · Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea · Persbericht

13 februari 2024 · Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio · Persbericht

19 januari 2024 · Cresemba® sales in Latin America trigger first sales milestone payment to Basilea · Persbericht

15 januari 2024 · Basilea announces acquisition of preclinical antibiotics program from Spexis · Persbericht

5 januari 2024 · Basilea provides portfolio status update · Persbericht

20 december 2023 · Basilea announces accelerated loan repayment · Persbericht

11 december 2023 · Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis · Persbericht

20 november 2023 · Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year · Persbericht

13 november 2023 · Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal · Persbericht

31 oktober 2023 · Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent · Persbericht

19 oktober 2023 · Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infections · Persbericht

17 oktober 2023 · Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023 · Persbericht

2 oktober 2023 · Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole · Persbericht

28 september 2023 · Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia · Persbericht

15 augustus 2023 · Basilea reports strong revenue and profit growth in first half-year 2023 · Persbericht

Mijn selecties